Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart in Moderate to Severe Atopic Dermatitis
NCT06863961Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2025
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of afimkibart in atopic dermatitis (AD), sponsored by Roche. Started Apr 2025; status: active, not recruiting.
02
Drugs
afimkibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06863961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863961.